J.P. Morgan downgrades Bruker stock and keeps USD 70.00 target

Published on 10/15/2026 at 22:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 838.50 million, up 5.20 percent year over year. Bruker stock costs EUR 50.40 on October 15, 2026.

Analyst view and upcoming results

J.P. Morgan downgraded Bruker to Neutral on October 14, 2026, while keeping a USD 70.00 target.
Second-quarter 2026 revenue reached USD 838.50 million, up 5.20 percent year over year.
Bruker stock costs EUR 50.40 at Lang & Schwarz on October 15, 2026 at 10:38 p.m. CEST.
MarketBeat estimates the next earnings announcement for November 2, 2026.

BRKR, US1167941087, Illustration mit AI erstellt.

J.P. Morgan downgraded Bruker to Neutral from Overweight on October 14, 2026, while maintaining a USD 70.00 price target, according to GuruFocus. Bruker stock was trading at EUR 50.40 at Lang & Schwarz on October 15, 2026 at 10:38 p.m. CEST.

Revenue growth meets a loss

Bruker's second-quarter 2026 revenue was USD 838.50 million, up 5.20 percent from the same quarter a year earlier, while net loss reached USD 62.90 million. Simply Wall St reported the revenue comparison and a USD 0.41 loss per share for the period. The combination puts revenue momentum beside a weaker earnings picture.

Stock sits below its yearly high

The Nasdaq-listed stock stood at USD 56.54 after the U.S. session on October 15, 2026, with a USD 55.60 previous close. Its 52-week range was USD 32.37 to USD 66.98, leaving the latest U.S. price 15.59 percent below the high. Trading volume was 1,954,853 shares against an average of 2,267,376.

On October 14, 2026, J.P. Morgan cited concern about Bruker's exposure to the Academia and Government segment and uncertainty around revenue growth. The USD 70.00 target stands 23.67 percent above the USD 56.54 Nasdaq price. The company also remains loss-making on the latest trailing figures, so sales growth and execution are central valuation markers.

Results date and peer values

MarketBeat estimates that Bruker will report third-quarter 2026 results on November 2, 2026, before the market opens. The page also lists consensus revenue of USD 865.19 million and consensus earnings per share of USD 0.4188 for that quarter.

Comparison with peers

Bruker: P/E minus 80.88, market capitalization USD 8.6 billion
Danaher (NYSE, USD): P/E 41.12, market capitalization USD 162.7 billion
Thermo Fisher Scientific (NYSE, USD): P/E 37.47, market capitalization USD 257.5 billion

Price and valuation markers

Bruker's market capitalization was USD 8.6 billion, while its trailing P/E was minus 80.88. The contrast with Danaher's P/E of 41.12 and Thermo Fisher's P/E of 37.47 reflects Bruker's latest loss position rather than a like-for-like earnings valuation. Bruker develops scientific instruments, analytical systems and diagnostic solutions for research, healthcare and industrial customers.

Trading snapshot

Bruker was trading at EUR 50.40 at Lang & Schwarz on October 15, 2026 at 10:38 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Bruker stock.